

A meta-analytic comparison of echocardiographic stressors

Yoshinori Noguchi¹, Shizuko Nagata-Kobayashi², James E Stahl³ & John B Wong⁴

¹Division of General Internal Medicine, Department of Medicine, Fujita Health University School of Medicine, Toyoake, Japan; ²Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan; ³MGH-Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA; ⁴Division of Clinical Decision Making, Informatics and Telemedicine in the Department of Medicine, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, USA

Received 29 June 2004; accepted in revised form 7 October 2004

Key words: meta-analysis, SROC analysis, stress echocardiography, test characteristics

Abstract

Background: The relative performance of alternative stressors for stress echocardiography for the diagnosis of coronary artery disease (CAD) is not well established. **Methods:** All studies published between 1981 to December 2001 who met inclusion criteria were included in this analysis. We performed a summary receiver operator characteristic (SROC) analysis and calculated weighted mean of the likelihood ratio and sensitivity/specificity. A covariate analysis using meta-regression methods was also performed. **Results:** Forty-four studies presented data on Exercise, 11 on Adenosine, 80 on Dobutamine, 40 on Dipyridamole, 16 on transatrial pacing transesophageal echocardiography (Tap-TEE), and 7 on transatrial pacing transthoracic echocardiography (Tap-TTE). SROC analysis showed that the following order of most discriminatory to least: Tap-TEE, Exercise, Dipyridamole, Dobutamine and Adenosine. Weighted means sensitivity/specificity were Exercise: 82.6/84.4%, Adenosine: 68.4/80.9%, Dobutamine: 79.6/85.1%, Dipyridamole: 71.0/92.2%, Tap-TTE: 90.7/86.1%, and Tap-TEE: 86.2/91.3%. Covariate analysis showed that the discriminatory power of Exercise decreased with increasing mean age. **Conclusions:** Tap-TEE is a very accurate test for both ruling in and ruling out CAD although its invasiveness may limit its clinical acceptability. Exercise is a well-balanced satisfactory test for both ruling in and ruling out but performance might be lower for the elderly. Dobutamine offers a reasonable compromise for Exercise. Dipyridamole might be good for ruling in but not for ruling out CAD. The incapability in ruling-out CAD was a major problem in clinical application of the stress. Adenosine was the least useful stressor in diagnosing CAD.

Abbreviations: SROC – summary receiver operator characteristic; TEE – transesophageal echocardiography; TTE – transthoracic echocardiography

Introduction

Two-dimensional (2D) echocardiography is widely used as a non-invasive diagnostic test for detecting coronary artery disease (CAD) and can be performed with non-pharmacologic stimulation,

such as, exercise or transatrial pacing, or pharmacologic stimulation including dobutamine, dipyridamole, or adenosine assessed with either transthoracic or transesophageal echocardiography. The relative performance of these alternative approaches for the diagnosis of CAD is not well

established. Therefore, we performed a meta-analysis and applied current methodological recommendations to compare the diagnostic performance of alternative echocardiographic stressors for detecting CAD using summary receiver operator characteristic (SROC) curve analysis.

Method

Data extraction

We searched MEDLINE from 1966 to December 2001, and of EMBASE from 1989 to 2001 for all relevant human studies written in English. The MESH and free text search strategy included echocardiography and coronary disease and sensitivity and specificity and (adenosine or dobutamine or dipyridamole or cardiac pacing artificial or exercise or exercise test). Bibliographies of original and review articles were also hand inspected for additional articles.

Inclusion criteria were prespecified and consisted of the following: (1) Coronary angiography was the gold standard. (2) CAD at coronary angiography was specified as percent stenosis. (3) Criterion for a positive stress echocardiography was described explicitly. (4) Absolute numbers of true-positive, false-negative, false-positive, and true-negative were available or derivable from the data reported. (5) Healthy controls were not used as a non-diseased population (i.e., Studies were not case-controlled).

Studies were excluded if they were performed exclusively on specific clinical subsets of patients such as acute myocardial infarction (MI), unstable angina, post-heart transplantation, left bundle branch block (LBBB), post-percutaneous transluminal coronary angioplasty (PTCA), post-CABG, pacemaker, Kawasaki disease, aortic stenosis, dilated or hypertrophic cardiomyopathy, and single vessel disease. Two independent investigators reviewed all articles and any discrepancies were resolved by consensus with the third investigator.

Data extracted from studies consisted of the positive test criteria for stress echocardiography, definition of CAD on coronary angiography, the number of true-positive, false-negative, false-positive,

and true-negative cases based on these criteria, demographic data (first author, journal, city, and institution), publication year, study population characteristics (age, gender, prevalence of CAD, prior MI, unstable angina, washout of beta blocker), and type of stressor used.

Assessment of study quality

To evaluate study quality in the assessment of diagnostic tests, Lijmer's scoring method was used [1]. It considers blinded interpretation of test results, blinded interpretation of gold standard results, consecutive vs. non-consecutive patient enrollment, prospective vs. retrospective data collection, verification bias, detailed patient population description, detailed description of tests, detailed description of the gold standard used, and case-controlled or not case-controlled. Each item was scored as 1 point if the corresponding criterion is fulfilled (Appendix A). The minimum number of points possible is 0, and maximum is 9. But studies in our analysis ranged in score from 3 to 9, because our inclusion criteria excluded studies with case-control design or insufficient details of the test and the gold standard. Studies were divided into two categories low or high quality based on the quality score cutoff of 6.

Statistical analysis

The studies were divided into subgroups according to stressors. The validity for SROC analysis was checked according to the Midgette procedure [2]. Monotonically increasing relationship between the true positive rate (TPR) and the false positive rate (FPR) was examined using the non-parametric Spearman correlation test in each subgroup. If the Spearman correlation test was positive, we constructed SROC curves. If not, we reported only the weighted mean of the positive and negative likelihood ratio ($LR \pm$), sensitivity, and specificity for each subgroup.

SROC analysis

To adjust for variation in positive test criteria among studies, SROC curves were generated for each stressor subgroup using the methodology of

Littenberg and Moses [3]. Meta-regression techniques were used to adjust for clinically relevant covariates and hypothesis testing [3, 4]. Clinical covariates of interest including mean age, publication year, percentage of female patients, prevalence of CAD, prevalence of multi-vessel disease, presence of verification bias, quality score of primary study, the presence or absence of patients with previous MI in the study, whether or not patients underwent beta-blocker washed out, and CAD definition of 50% stenosis vs. more than 70% stenosis were assessed in univariate models. The covariates, identified as statistically significant in univariate analysis were then examined in a multivariate regression model.

Weighted-pooled analysis

We calculated the likelihood ratios for positive test results and negative test results ($LR \pm$) from the results of each study ($LR + = TPR/FPR$, $LR - = FNR/TNR$). Weighted-pooled means of sensitivity and specificity were also calculated. Tests for homogeneity were performed for the $LR \pm$ using Q statistic [5] with a cut-off p -value of 0.10 being considered significant. If heterogeneity was rejected, a Mantel-Haenszel fixed-effect model was used for the weighted-pooled analysis. Otherwise, a random-effects model (DerSimonian and Laird) was used [6].

Sensitivity analysis

Sensitivity analyses for SROC and weighted-pooled analysis were performed using high quality studies excluding low quality studies. β coefficients for SROC curve and weighted mean of LRs, sensitivity, and specificity were recalculated.

Statistical analysis was performed by using STATA statistical software [7]. Results are expressed as mean and 95% confidence interval, and a p -value less than 0.05 (two-sided) were considered statistically significant, unless otherwise indicated.

Results

Overview of studies

The literature search yielded 805 citations for Medline and 672 citations for Embase. Applying the

inclusion and exclusion criteria, we identified 123 articles involving results for 197 tests because some studies included data on more than one test. Four articles were judged to be multiple publications originating from two identical study populations, so two were excluded. Uncommon pharmacological stressors such as isoproterenol and arbutamine were also excluded from this analysis. A small number of test modalities including two studies of Dobutamine-TEE, three studies of oral Dipyridamole stress, and one study of Dipyridamole-TEE were also excluded because of paucity of data. Thus our final data set included 44 studies with exercise stress [8–51], 11 with adenosine [33, 43, 52–60], 80 with dobutamine [29, 34, 36, 48, 51, 56, 58, 61–133], 40 with dipyridamole [34, 35, 39, 48, 62, 69, 75, 79, 93, 99, 100, 118, 119, 122, 134–159], 13 with Transatrial-pacing (6 involving transesophageal [160–165] and 7 involving transthoracic echocardiography (Table 1) [16, 35, 161–170].

Assessment of study quality

The mean quality score was 7.3 ± 1.2 SD. The majority of studies (93.6%) were classified as high quality (quality score > 6).

SROC curve analysis

Spearman rank correlation coefficients were positive for Exercise, Adenosine, Dobutamine, Dipyridamole, and Tap-TTE, and negative for Tap-TEE, so SROC analysis was not performed for the Tap-TEE. SROC analysis results are presented in Figure 1. The shape of the SROC curve for Dobutamine was different from other curves, with Dobutamine having a sharper increase in TPR for a given increase in the FPR. We compared the discrimination of each test by examining multiple SROC curves. The β coefficients of stressor subgroups were Exercise: $\beta = -0.94$, $p = 0.15$, Dipyridamole: $\beta = -1.02$, $p = 0.12$, Dobutamine: $\beta = -1.10$, $p = 0.09$, Adenosine: $\beta = -1.90$, $p = 0.01$ with Tap-TEE subgroup as reference. Thus, our results suggest the following order of most discriminatory to least: Tap-TEE, Exercise, Dipyridamole, Dobutamine and Adenosine. However, there was no significant difference

Table 1. Features of the studies included in meta-analysis.

Author	Reference number	Year	Stressor	TP	FP	FN	TN	Mean age (y)	Women (%)	With CAD (%)	With Multi-VD (%)	CAD definition (%)	With prior MI	With prior MI with prior MI (%)	Unstable angina included	Current beta blocker usage	Verification bias	Quality	Modulator
Berberich SN	13	1981	Exercise	14	0	1	7	62	36.4	68.2	NA	50	Y	NA	NA	Y	Yes	5	
Maurer G	14	1981	Exercise	19	1	4	12	53	22.0	63.9	47.2	50	Y	NA	NA	Y	No	8	
Mitamura H	15	1981	Exercise	29	1	9	6	51	4.4	84.4	57.8	50	Y	51.1	NA	N	Less likely	7	
Morganroth J	16	1981	Exercise	19	1	13	10	51	32.6	73.2	NA	50	Y	NA	N	NA	No	7	
Limacher MC	17	1983	Exercise	51	2	5	15	54	13.7	76.7	61.6	50	Y	NA	N	Y	Likely	6	
Robertson WS	18	1983	Exercise	17	1	4	3	54	16.7	84.0	52.0	75	Y	NA	NA	Y	Likely	7	
Visser CA	19	1983	Exercise	19	1	6	12	55	17.3	65.8	NA	50	N	0.0	N	NA	Less likely	9	
Armstrong WF	20	1986	Exercise	35	2	9	13	54	21.1	74.6	NA	50	N	0.0	NA	Y	Likely	8	
Illiceto S	21	1986	Exercise	28	1	11	18	NA	NA	NA	36.2	75	NA	NA	NA	N	No	7	
Ryan T	22	1988	Exercise	31	0	9	24	58	39.1	62.5	23.4	50	Y	NA	NA	Y	Yes	7	
Sawada SG	23	1989	Exercise	24	4	4	25	57	100.0	49.1	NA	50	N	0.0	NA	Y	Likely	7	
Alam M	24	1991	Exercise	36	0	9	3	61	31.3	93.8	47.9	50	N	0.0	NA	Y	Less likely	8	
Crouse LJ	25	1991	Exercise	170	19	5	34	62	32.9	76.8	46.5	50	N	0.0	NA	Y	Likely	7	
Galandi G	26	1991	Exercise	25	1	2	25	54	13.2	50.9	24.5	70	N	0.0	NA	Y	Yes	7	
Pozzoli MM	27	1991	Exercise	35	1	14	25	52	13.3	65.3	21.3	50	Y	NA	NA	Y	Yes	6	
Fioretti PM	28	1992	Exercise	15	0	7	2	58	23.1	91.7	NA	50	Y	NA	N	No	8		
Marwick TH	29	1992	Exercise	96	5	18	31	57	21.3	76.0	36.0	50	Y	NA	NA	N	No	8	
Marwick TH	30	1992	Exercise	63	0	7	4	60	18.9	94.6	NA	50	Y	NA	N	N	Likely	5	
Quinones MA	31	1992	Exercise	64	3	22	23	57	33.2	76.8	40.2	50	Y	NA	NA	Y	Yes	6	
Salustri A	32	1992	Exercise	20	2	10	12	59	20.5	68.2	0.0	50	Y	36.4	N	Y	Likely	6	
Salustri A	33	1992	Exercise	11	2	4	4	59	19.0	71.4	NA	50	Y	33.3	NA	Y	Yes	6	
Cohen JL	34	1993	Exercise	29	2	8	13	63	1.9	71.2	40.4	70	Y	NA	N	N	No	8	
Hecht HS	35	1993	Exercise	46	4	5	16	58	14.1	71.8	NA	50	Y	NA	NA	Y	No	7	
Hecht HS	36	1993	Exercise	128	6	9	37	56	13.9	76.1	45.6	50	Y	NA	NA	Y	Likely	6	
Hecht HS	37	1993	Exercise	78	4	16	38	59	11.0	69.1	NA	50	Y	NA	NA	Y	Less likely	7	
Kujacic VG	38	1993	Exercise	19	1	7	2	59	0.0	89.7	48.3	50	NA	NA	N	N	Likely	7	
Beleslin BD	39	1994	Exercise	104	3	15	14	50	14.7	87.5	8.1	50	Y	56.6	N	N	No	9	
Marangelli V	40	1994	Exercise	31	3	4	22	58	15.9	58.3	31.7	75	N	0.0	NA	N	No	8	
Marwick TH	41	1994	Exercise	49	6	7	24	59	30.2	65.1	39.5	50	N	0.0	N	Y	No	8	
Williams MJ	42	1994	Exercise	29	6	4	31	60	100.0	47.1	20.0	50	N	0.0	N	NA	Less likely	9	
Atar D	43	1995	Exercise	49	2	9	10	59	NA	82.9	54.3	50	NA	NA	N	N	Less likely	8	
Bjornstad KS	44	1995	Exercise	26	2	5	4	58	18.9	83.8	59.5	50	Y	NA	N	N	No	8	
Marwick TH	45	1995	Exercise	47	19	12	83	60	100.0	36.6	16.8	50	N	0.0	NA	NA	Yes	7	
Marwick TH	46	1995	Exercise	44	8	13	14	NA	40.8	42.2	20.4	50	N	0.0	NA	NA	Less likely	8	
Roger VL	47	1995	Exercise	94	6	18	14	NA	NA	84.3	NA	50	NA	NA	NA	Y	Likely	3	
Tawa C.B	48	1996	Exercise	31	2	2	10	58	29.9	73.3	33.3	70	Y	NA	N	Y	Yes	7	
Tian J	49	1996	Exercise	28	1	4	13	54	17.0	69.6	45.7	50	Y	NA	N	NA	No	8	
Toumanidis ST	50	1996	Exercise	18	10	7	35	54	28.6	35.7	22.9	50	N	0.0	NA	Y	Likely	7	
Roger VL	51	1997	Exercise	197	52	55	36	65	28.2	74.1	50.9	50	N	0.0	NA	NA	Yes	7	
Badruddin SM	52	1999	Exercise	42	1	15	9	59	8.1	85.1	62.7	50	Y	NA	N	Y	Yes	7	
Loimaala A	53	1999	Exercise	40	9	4	7	55	33.3	73.3	30.0	50	Y	15.0	N	N	Less likely	7	

54	Peteiro J	1999	Exercise	51	4	19	5	62	22.5	78.7	59.6	50	50	Y	NA	NA	NA	Likely	6
55	Chaudhry FA	2000	Exercise	12	3	4	9	66	0.0	57.1	42.9	50	50	Y	NA	NA	NA	Yes	5
56	Pastorski T	2001	Exercise	95	5	21	127	53	33.0	46.8	56.5	50	50	N	NA	NA	NA	Likely	7
57	Nguyen T	1990	Adenosine	2	0	18	5	62	35.0	80.0	NA	50	50	Y	NA	N	N	Less likely	8
58	Edlund A	1991	Adenosine	31	1	4	1	NA	16.2	94.6	45.9	70	70	NA	NA	N	NA	Likely	6
59	Zoghbi WA	1991	Adenosine	46	2	12	17	59	15.1	74.0	32.9	75	70	Y	NA	N	Y	Less likely	8
60	Amanullah AM	1993	Adenosine	21	0	13	6	61	20.0	85.0	NA	50	50	Y	NA	Y	N	No	8
38	Kujacic VG	1993	Adenosine	22	0	4	3	59	0.0	89.7	48.3	50	50	NA	NA	N	N	Likely	6
61	Marwick T	1993	Adenosine	34	5	25	33	56	28.9	60.8	28.9	50	50	N	0.0	NA	Y	No	6
62	Fukai TS	1995	Adenosine	22	0	12	4	61	37.2	89.5	36.8	75	75	Y	NA	N	NA	Less likely	9
63	Anthopoulos LP	1996	Adenosine	59	28	30	3	75	40.0	74.2	58.3	50	50	Y	NA	N	NA	No	9
64	Djordjevic Dikic AD	1996	Adenosine	30	0	10	18	50	12.1	69.0	12.1	50	50	Y	41.4	N	Y	No	8
48	Tawa CB	1996	Adenosine	29	1	4	11	58	29.9	73.3	33.3	70	70	Y	NA	N	Y	Yes	7
65	Miyazono Y	1998	Adenosine	46	5	16	45	99	27.7	55.4	13.4	70	70	Y	NA	NA	Y	No	8
66	Cohen JL	1991	Dobutamine	44	1	7	18	62	0.0	72.9	50.0	70	70	Y	NA	N	Y	No	8
67	Previtali M	1991	Dobutamine	19	0	9	7	53	14.3	80.0	34.3	70	70	Y	NA	NA	N	Likely	7
68	Sawada SG	1991	Dobutamine	31	3	4	17	59	37.9	63.6	25.5	50	50	Y	NA	NA	Y	Yes	7
69	Epstein MK	1992	Dobutamine	50	4	3	4	59	29.5	86.9	47.5	50	50	NA	NA	NA	Y	No	8
70	Marcovitz PA	1992	Dobutamine	105	11	4	21	60	40.4	77.3	33.3	50	50	Y	NA	NA	Y	Likely	6
71	Mazeika PK	1992	Dobutamine	28	1	8	13	54	12.0	72.0	48.0	70	70	Y	NA	N	Y	No	7
72	Meneill AJ	1992	Dobutamine	33	3	14	29	NA	18.1	58.8	NA	50	50	Y	NA	N	Y	No	8
73	Salustri A	1992	Dobutamine	20	3	17	12	58	26.9	71.2	32.7	50	50	Y	NA	N	Y	Less likely	7
74	Salustri A	1992	Dobutamine	16	4	14	14	58	30.4	60.9	39.1	50	50	Y	NA	N	Y	Less likely	8
75	Segar DS	1992	Dobutamine	63	4	3	18	59	38.8	75.0	NA	50	50	NA	NA	NA	NA	Likely	5
34	Cohen JL	1993	Dobutamine	32	2	5	13	63	1.9	71.2	40.4	70	70	Y	NA	N	Y	No	8
76	Forster T	1993	Dobutamine	9	1	3	8	62	44.8	57.1	NA	50	50	Y	NA	NA	Y	Yes	6
77	Gunalp B	1993	Dobutamine	15	1	3	8	47	14.8	66.7	33.3	50	50	N	0.0	NA	N	Likely	7
61	Marwick T	1993	Dobutamine	50	7	9	31	56	28.9	60.8	28.9	50	50	N	0.0	NA	Y	No	6
78	Marwick T	1993	Dobutamine	102	13	40	62	58	28.1	65.4	34.1	50	50	N	0.0	N	Y	No	8
79	Mazeika PK	1993	Dobutamine	24	1	13	13	54	11.8	72.5	49.0	50	50	Y	NA	N	N	No	9
80	Previtali M	1993	Dobutamine	45	4	12	19	53	22.5	71.3	41.3	50	50	Y	NA	N	N	Less likely	8
81	Takeuchi M	1993	Dobutamine	63	3	11	43	63	25.8	61.7	30.8	50	50	Y	NA	N	Y	Less likely	8
82	Warner MF	1993	Dobutamine	1	0	11	1	61	56.3	92.9	NA	50	50	Y	NA	NA	N	Less likely	8
39	Beleslin BD	1994	Dobutamine	98	4	21	13	50	14.7	87.5	8.1	50	50	Y	56.6	N	N	No	9
83	Mairesse GH	1994	Dobutamine	63	7	20	39	56	26.4	64.3	34.1	50	50	N	0.0	N	Y	No	9
41	Marwick TH	1994	Dobutamine	30	5	26	25	59	30.2	65.1	39.5	50	50	N	0.0	N	Y	No	8
84	Ostojic M	1994	Dobutamine	98	4	33	15	51	16.7	87.3	10.7	50	50	Y	50.7	N	Y	Less likely	8
85	Panza JA	1994	Dobutamine	55	0	7	14	60	18.4	81.6	NA	70	70	Y	NA	NA	N	Less likely	8
86	Prince CR	1994	Dobutamine	23	4	2	52	62	14.5	30.9	19.8	70	70	Y	NA	N	N	Less likely	8
87	Sahin M	1994	Dobutamine	33	3	11	20	58	29.2	64.6	36.9	50	50	Y	NA	N	N	Less likely	9
88	Santiago P	1994	Dobutamine	42	10	11	16	67	30.1	67.1	NA	70	70	NA	NA	NA	N	Yes	5
89	Senior R	1994	Dobutamine	41	1	3	16	63	27.9	72.1	49.2	50	50	Y	NA	N	N	Likely	7
90	Castini D	1995	Dobutamine	26	0	12	6	56	6.8	86.4	40.9	70	70	Y	NA	Y	N	Likely	7
91	Chan RKM	1995	Dobutamine	63	2	9	10	61	20.6	85.7	50.0	70	70	Y	NA	N	NA	Less likely	9
92	Drouot EG	1995	Dobutamine	60	3	5	8	60	42.1	85.5	NA	50	50	Y	NA	NA	NA	Yes	4
93	Frohwein S	1995	Dobutamine	22	1	5	12	NA	0.0	67.5	25.0	50	50	Y	NA	N	Y	Less likely	7
94	Geleijnse ML	1995	Dobutamine	103	17	40	63	58	31.4	64.1	27.8	50	50	N	0.0	N	Y	Likely	7
95	Latham AP	1995	Dobutamine	64	7	22	13	63	39.3	81.1	NA	50	50	Y	NA	NA	NA	Yes	5
96	Mairesse GH	1995	Dobutamine	15	2	0	7	61	25.0	62.5	NA	50	50	Y	NA	NA	NA	Likely	6
97	Reis G	1995	Dobutamine	22	1	1	6	47	37.1	76.7	NA	50	50	Y	NA	NA	NA	Yes	6

Table 1. Continued

Author	Reference number	Year	Stressor	TP	FP	FN	TN	Mean age (y)	Women (%)	With CAD (%)	With Multi-VD (%)	CAD definition (%)	With prior MI	With prior MI with prior MI (%)	Unstable angina included	Current beta blocker usage	Verification bias	Quality	Modulator
Sochowski RA	98	1995	Dobutamine	17	4	7	18	58	32.6	52.2	28.3	70	N	0.0	N	N	No	8	NA
Anthopoulos LP	63	1996	Dobutamine	77	5	12	26	75	40.0	74.2	58.3	50	Y	NA	N	NA	No	9	NA
De Bello V	99	1996	Dobutamine	29	1	9	6	53	26.7	84.4	42.2	50	N	0.0	N	N	Yes	8	Atropine
Elhendy A	100	1996	Dobutamine	12	1	8	3	59	30.6	83.3	37.5	50	Y	NA	NA	Yes	6	Atropine	
Elhendy A	101	1996	Dobutamine	87	3	24	19	60	23.5	84.1	59.8	50	Y	NA	N	Y	Likely	6	Atropine
Hoffmann R	102	1996	Dobutamine	72	7	23	48	46	20.5	63.3	24.0	50	Y	9.3	N	Y	No	8	Atropine
Iwase MM	103	1996	Dobutamine	50	3	13	29	59	30.2	65.6	29.2	70	Y	NA	N	N	No	9	NA
Pingitore A	104	1996	Dobutamine	87	2	5	16	60	16.7	83.6	46.4	50	Y	NA	N	Y	Yes	7	Atropine
San Roman JA	105	1996	Dobutamine	49	2	14	37	62	43.0	61.8	33.3	50	N	0.0	N	Y	No	8	Atropine
Senior R	106	1996	Dobutamine	27	0	2	14	89	25.6	67.4	51.2	50	Y	NA	N	N	Less likely	9	NA
Takeuchi M	107	1996	Dobutamine	15	4	5	46	65	100.0	28.6	15.7	50	N	0.0	N	Y	Less likely	9	Atropine
Yeo TC	108	1996	Dobutamine	32	6	4	22	57	42.2	56.3	29.7	70	Y	NA	NA	Likely	7	Atropine	
Hennessy TG	109	1997	Dobutamine	234	17	40	26	60	27.8	86.4	34.4	50	Y	NA	N	N	Less likely	8	Atropine
Hennessy TG	110	1997	Dobutamine	32	6	7	7	56	28.8	75.0	69.2	50	Y	26.9	N	N	Likely	7	Atropine
Ho YL	111	1997	Dobutamine	35	3	3	10	56	23.5	74.5	56.9	50	Y	NA	N	Y	No	8	NA
Ho YL	112	1997	Dobutamine	152	13	10	48	58	19.3	72.6	55.6	50	Y	NA	N	Y	No	8	Atropine
Oguzhan A	113	1997	Dobutamine	44	2	5	19	51	15.7	70.0	45.7	70	Y	NA	N	N	No	8	Atropine
Vitarelli A	114	1997	Dobutamine	41	2	7	9	52	35.6	81.4	44.1	70	Y	NA	N	N	Likely	5	NA
Elhendy A	115	1998	Dobutamine	164	10	57	59	58	30.3	76.2	46.9	50	Y	NA	N	NA	Likely	6	Atropine
Elhendy A	116	1998	Dobutamine	48	3	18	15	60	36.9	78.6	50.0	50	Y	NA	N	NA	Likely	7	Atropine
Elhendy A	117	1998	Dobutamine	171	9	57	58	NA	NA	77.3	48.5	50	Y	NA	N	NA	Likely	6	Atropine
Elhendy A	118	1998	Dobutamine	35	2	10	23	58	100.0	64.3	25.7	50	Y	NA	N	NA	Less likely	7	Atropine
Hennessy TG	119	1998	Dobutamine	97	3	101	17	62	27.1	90.8	NA	50	Y	NA	N	NA	No	8	Atropine
Ho YL	120	1998	Dobutamine	27	4	2	18	62	100.0	56.9	39.2	50	Y	NA	N	NA	No	7	N
Ho YL	121	1998	Dobutamine	26	4	3	23	60	26.7	51.8	37.5	50	Y	NA	N	Y	No	6	Atropine
Khattar RS	122	1998	Dobutamine	50	5	24	21	62	30.0	74.0	56.0	50	Y	NA	N	N	No	8	N
San Roman JA	123	1998	Dobutamine	52	4	14	32	64	51.0	64.7	33.3	50	N	0.0	N	Y	No	9	Atropine
Santoro GM	124	1998	Dobutamine	20	1	13	26	NA	NA	55.0	35.0	70	N	0.0	N	N	No	6	Atropine
Shaheen J	125	1998	Dobutamine	37	4	5	18	NA	NA	65.6	31.3	70	NA	NA	NA	NA	Yes	5	Atropine
Elhendy A	126	1999	Dobutamine	61	3	12	14	57	20.0	81.1	65.6	50	Y	100.0	NA	NA	Less likely	7	Atropine
Fragasso G	127	1999	Dobutamine	50	9	7	35	61	45.5	56.4	36.6	50	N	0.0	NA	N	No	8	N
Herzog CA	128	1999	Dobutamine	14	6	13	17	51	40.0	54.0	26.0	50	Y	8.0	N	Y	Less likely	8	Atropine
Hoffmann R	129	1999	Dobutamine	132	22	51	78	56	21.6	64.7	26.9	50	Y	16.6	N	N	No	7	Atropine
Loimaa A	53	1999	Dobutamine	42	6	2	10	55	33.3	73.3	30.0	50	Y	15.0	N	N	Less likely	7	Atropine
Nagel E	130	1999	Dobutamine	81	10	28	44	60	29.3	63.4	40.7	50	N	0.0	N	N	No	9	Atropine
Ozdemir K	131	1999	Dobutamine	39	3	3	18	52	20.8	66.7	42.9	50	Y	NA	N	N	No	8	Atropine
Therrie T	132	1999	Dobutamine	25	13	7	40	60	NA	37.6	NA	50	Y	NA	N	N	No	7	Atropine
Ariff B	133	2000	Dobutamine	30	6	7	23	NA	31.8	56.1	NA	70	NA	NA	NA	NA	Likely	3	Atropine
Joseph T	134	2000	Dobutamine	18	8	10	27	65	13.2	44.4	20.6	70	Y	NA	N	N	Less likely	9	Atropine
Smart SC	135	2000	Dobutamine	238	14	42	92	61	34.5	72.5	43.8	50	Y	NA	N	NA	No	7	Atropine

136	Ahmad M	2001	Dobutamine	34	6	24	26	NA	53.4	64.4	41.1	50	Y	NA	NA	NA	Yes	7	Atropine
137	Dolan MS	2001	Dobutamine	65	4	26	17	61	NA	81.3	33.0	70	Y	NA	NA	NA	Likely	6	N
56	Pasierski T	2001	Dobutamine	86	3	30	129	53	33.0	46.8	56.5	50	N	NA	NA	NA	Likely	7	Atropine
138	Peteiro J	2001	Dobutamine	26	1	6	8	63	22.0	78.0	48.8	50	Y	NA	NA	NA	Less likely	9	Atropine
139	Picano EA	1985	Dipyrdamole	28	0	22	16	50	12.1	75.8	30.3	70	Y	NA	N	N	Likely	7	
140	Picano E	1986	Dipyrdamole	53	0	19	21	55	16.1	77.4	51.6	70	Y	NA	N	N	Less likely	9	
141	Picano E	1986	Dipyrdamole	27	0	23	33	51	20.5	60.2	NA	70	Y	NA	NA	NA	Less likely	9	
142	Picano E	1986	Dipyrdamole	25	0	15	22	53	17.7	64.5	NA	70	Y	NA	N	N	Likely	6	
143	Picano E	1987	Dipyrdamole	18	0	7	15	52	16.4	62.5	NA	70	Y	NA	N	N	Likely	7	
144	Masini M	1988	Dipyrdamole	31	3	8	41	55	100.0	47.0	NA	70	Y	NA	N	N	Less likely	7	
145	Picano E	1988	Dipyrdamole	17	0	2	6	53	8.0	76.0	NA	70	Y	NA	N	N	Yes	7	
146	Picano E	1988	Dipyrdamole	48	1	21	24	53	24.5	73.4	NA	70	N	0.0	NA	Y	Likely	8	
147	Picano E	1989	Dipyrdamole	218	9	82	65	54	23.4	80.2	45.2	50	Y	NA	NA	Y	Likely	8	
148	Ferrara N	1991	Dipyrdamole	71	0	19	19	62	37.7	82.6	NA	70	Y	NA	N	N	No	7	
149	Mandysova E	1991	Dipyrdamole	21	0	19	13	55	9.4	75.5	NA	70	Y	NA	NA	N	Less likely	7	Handgrip
150	Perin EC	1991	Dipyrdamole	11	0	8	6	62	24.0	76.0	NA	50	NA	NA	NA	NA	Yes	6	
151	Picano E	1991	Dipyrdamole	27	1	6	16	55	38.0	66.0	NA	70	NA	NA	NA	NA	Likely	7	
67	Previtali M	1991	Dipyrdamole	16	0	12	7	53	14.3	80.0	34.3	70	Y	NA	NA	N	Likely	7	
152	Agati L	1992	Dipyrdamole	22	0	2	8	60	31.3	75.0	56.3	70	Y	NA	NA	N	Less likely	8	
153	Lattanzi F	1992	Dipyrdamole	20	0	1	7	54	10.7	75.0	NA	70	Y	NA	N	NA	No	8	
154	Mazeika P	1992	Dipyrdamole	16	1	24	14	55	25.5	72.7	NA	70	NA	NA	N	N	No	8	
74	Salutri A	1992	Dipyrdamole	18	2	10	16	58	30.4	60.9	39.1	50	Y	NA	NA	Y	Less likely	8	
155	Bjoernstad K	1993	Dipyrdamole	18	0	8	4	60	46.7	86.7	53.3	50	Y	NA	NA	Y	Yes	7	
156	Picano EA	1993	Dipyrdamole	94	2	36	46	58	15.6	73.0	41.6	50	N	0.0	N	N	Likely	6	
80	Previtali M	1993	Dipyrdamole	34	1	23	22	53	22.5	71.3	41.3	50	Y	NA	N	N	Less likely	8	
39	Belesin BD	1994	Dipyrdamole	88	1	31	16	50	14.7	87.5	8.1	50	Y	56.6	N	N	No	9	
40	Marangelli V	1994	Dipyrdamole	15	2	20	23	58	15.9	58.3	31.7	75	N	0.0	NA	N	No	8	
84	Ostojic M	1994	Dipyrdamole	93	2	38	17	51	16.7	87.3	10.7	50	Y	50.7	Y	Y	Less likely	8	
157	Severi S	1994	Dipyrdamole	184	19	62	164	55	28.4	57.3	26.6	75	Y	0.0	N	N	No	8	
158	Bjoernstad KS	1995	Dipyrdamole	41	3	15	35	59	65.8	59.6	44.7	50	Y	29.2	N	N	Likely	7	
44	Bjoernstad KS	1995	Dipyrdamole	21	0	10	6	58	18.9	83.8	59.5	50	Y	NA	N	N	No	8	Atropine
159	Lanzarini L.R	1995	Dipyrdamole	45	1	10	5	53	4.9	90.2	44.3	50	Y	NA	N	N	Less likely	8	
98	Sochowski RA	1995	Dipyrdamole	16	19	8	3	58	32.6	52.2	28.3	70	Y	0.0	N	N	No	8	
104	Pingitore A	1996	Dipyrdamole	75	1	17	17	60	43.0	83.6	46.4	50	Y	NA	N	Y	Yes	7	Atropine
105	San Roman JA	1996	Dipyrdamole	49	1	14	38	62	16.7	61.8	33.3	50	N	0.0	N	Y	No	8	
160	Wagdi P	1996	Dipyrdamole	26	0	36	12	61	13.5	83.8	51.4	50	Y	NA	NA	Y	No	7	
161	Bjoernstad K	1997	Dipyrdamole	11	2	4	8	57	36.0	60.0	32.0	50	Y	NA	NA	NA	Yes	7	
123	San Roman JA	1998	Dipyrdamole	54	2	12	34	64	51.0	64.7	33.3	50	N	0.0	N	Y	No	9	
124	Santoro GM	1998	Dipyrdamole	18	1	15	26	NA	NA	55.0	35.0	70	N	0.0	NA	N	No	8	
127	Fragasso G	1999	Dipyrdamole	35	4	22	40	61	45.5	56.4	36.6	50	N	0.0	NA	N	No	8	
162	Gaddi O	1999	Dipyrdamole	12	0	1	11	55	0.0	54.2	29.2	50	N	0.0	N	N	No	9	
53	Loimaala A	1999	Dipyrdamole	41	4	3	12	55	33.3	73.3	30.0	50	Y	15.0	N	N	Less likely	7	Atropine
163	Purodi G	1999	Dipyrdamole	62	5	18	16	55	19.8	79.2	42.6	50	N	0.0	N	N	No	7	
164	Astarita C	2001	Dipyrdamole	18	0	5	30	58	45.3	43.4	20.8	50	N	NA	N	N	Less likely	8	
165	Zabalgoitia M	1991	TAP-TEE	19	1	2	14	63	0.0	58.3	19.4	70	N	0.0	N	Y	Likely	7	
166	de Cock CCO	1992	TAP-TEE	21	0	5	9	54	28.6	74.3	NA	50	Y	NA	NA	NA	Less likely	8	
167	Kamp O	1992	TAP-TEE	43	1	9	17	56	34.3	74.3	55.7	50	Y	NA	NA	NA	No	6	
168	Norris LP	1993	TAP-TEE	17	1	3	9	65	6.7	66.7	33.3	70	Y	NA	N	Y	No	9	
169	Hoffmann R	1994	TAP-TEE	21	5	4	28	55	16.7	41.7	NA	50	Y	NA	NA	NA	No	7	

Table 1. Continued

Author	Reference number	Year	Stressor	TP	FP	FN	TN	Mean age (y)	Women (%)	With CAD (%)	With Multi-V D (%)	CAD definition (%)	With prior MI	With prior MI with prior MI (%)	Unstable angina included	Current beta blocker usage	Verification bias	Quality	Modulator
Michael TA	170	1995	TAP-TEE	23	2	2	14	65	41.8	61.0	46.3	50	Y	NA	NA	NA	Yes	5	
Iliceto S	171	1985	TAP-TTE	51	3	5	22	51	13.6	69.1	44.4	75	Y	NA	NA	N	Less likely	7	
Iliceto S	21	1986	TAP-TTE	33	3	6	16	NA	NA	67.2	36.2	75	NA	NA	NA	N	No	6	
Matthews RV	172	1989	TAP-TTE	10	2	4	6	54	42.3	63.6	NA	70	Y	NA	N	NA	Likely	7	
Lauevictus A	173	1991	TAP-TTE	83	3	6	29	45	0.0	73.6	NA	70	Y	NA	Y	NA	Likely	5	
Marangelli V	40	1994	TAP-TTE	29	6	6	19	58	15.9	58.3	31.7	75	N	0.0	NA	N	No	7	
Michael TA	174	1996	TAP-TTE	44	2	7	12	NA	33.8	78.5	47.7	50	Y	NA	NA	NA	Likely	6	
Aitar S	175	2000	TAP-TTE	36	2	2	13	66	38.9	71.7	47.2	75	Y	NA	NA	NA	Less likely	9	

Y; yes; N; no; NA; not available in the report. Quality score; see Methods.

in overall discrimination among Tap-TEE, Exercise, Dipyridamole, and Dobutamine. Although Tap-TEE appears to be significantly better than Adenosine, the Bonferoni-adjusted *p* values in our analysis were approximately 0.005, so *p* values between 0.005 and 0.05 should be interpreted with caution.

In the analysis of covariates, the multivariate model showed that age for Exercise, percentage of female patients and 50% stenosis definition of CAD for Adenosine were significant predictors for the discriminatory power of the test. Prevalence of multi-vessel disease for Dobutamine was a positive predictor. In the Exercise subgroup, test discrimination decreased with increasing mean patient age ($\beta = -0.16, p < 0.01$). In the Adenosine subgroup, test discrimination decreased as the proportion of female patients increased ($\beta = -8.21, p = 0.03$) and in those studies using a 50% stenosis definition of CAD ($\beta = -1.50, p = 0.02$). In Dobutamine subgroup, test discrimination improved with prevalence of multiple vessel disease ($\beta = 1.67, p = 0.05$). No other covariates were statistically significant for any subgroups.

Weighted-pooled mean analyses

None of the subgroups met homogeneity criteria for LR+ and the Adenosine group was non-homogenous for LR- as well. LR+ was highest in Dipyridamole followed by Tap-TEE, Adenosine, Exercise, Dobutamine, and Tap-TTE. LR- was lowest in Tap-TEE/-TTE, followed by Exercise or Dobutamine, Dipyridamole, and Adenosine in ascending order. The homogeneity was rejected in Exercise, Adenosine, Dobutamine, and Dipyridamole for both sensitivity and specificity. Sensitivity was highest in Tap-TTE, followed by Tap-TEE, Exercise, Dobutamine, Dipyridamole, and Adenosine in descending order. Specificity was highest in Dipyridamole, followed by Tap-TEE, Tap-TTE, Dobutamine, Exercise, and Adenosine in descending order (Table 2).

Sensitivity analyses

Limiting the SROC curve analysis to high quality studies (quality score > 6) revealed that the order




Figure 1. The SROC curves are presented for a limited range not exceeding the observed range of true-positive and false-positive rates reported in studies for a given diagnostic test.

of the discriminatory test performance remained unchanged. The β coefficients were Exercise: $\beta = -0.75$, $p = 0.36$, Dipyridamole: $\beta = -0.92$, $p = 0.26$, Dobutamine: $\beta = -0.95$, $p = 0.24$, Adenosine: $\beta = -1.72$, $p = 0.07$ with Tap-TEE subgroup as reference.

Recalculating the weighted mean of LR using only high quality studies only resulted in small changes in the LR+ and LR-. The ratio of LR+ to LR- showed no significant changes. Sensitivity analysis for sensitivity/specificity also showed no significant changes (Table 3).

Discussion

The purpose of this study was to evaluate relative test performance of pharmacologic and non-pharmacologic echocardiographic stressors. Previous meta-analyses evaluating the efficacy of these stressors [171–175] have not rigorously fulfilled the methodological recommendations for meta-analysis, or have not evaluated all stressors currently used (Table 4). Therefore, we compared the diagnostic performance of all echocardiographic stressors currently in clinical use for detecting CAD by following methodological recommendations for meta-analysis of diagnostic test [176].

In this study, SROC curve analysis showed that Tap-TEE modality had the best test discrimination performance, followed by Exercise,

Table 2. Weighted means of LR+, LR-, sensitivity/specificity.

	Number of studies	LR +	95% CI	Heterogeneity	LR-	95% CI	Heterogeneity	LR + / LR - ratio
Exercise	44	7.5	6.3, 8.8	Yes*	0.3	0.2, 0.4	No	27.9
Adenosine	11	7.5	4.5, 10.6	Yes*	0.6	0.2, 0.9	Yes*	13.2
Dobutamine	80	6.6	5.8, 7.4	Yes*	0.3	0.3, 0.4	No	20.0
Dipyridamole	40	14.2	12, 16.5	Yes*	0.4	0.3, 0.4	No	36.9
TAP-TTE	7	6.0	4.1, 8	Yes*	0.2	-0.1, 0.5	No	34.7
TAP-TEE	6	10.9	7.4, 14.3	Yes*	0.2	-0.2, 0.5	No	61.4
	Number of studies	sensitivity	95% CI	Heterogeneity	Specificity	95% CI	Heterogeneity	
Exercise	44	82.6	79.8, 85.4	Yes*	84.4	80.4, 88.3	Yes*	
Adenosine	11	68.4	56.6, 80.2	Yes*	80.9	61.6, 100	Yes*	
Dobutamine	80	79.6	77, 82.2	Yes*	85.1	83, 87.2	Yes*	
Dipyridamole	40	71.0	67.3, 74.8	Yes*	92.2	89.3, 95.1	Yes*	
TAP-TTE	7	90.7	87.6, 93.8	No	86.1	80.4, 91.9	No	
TAP-TEE	6	86.2	81.1, 91.4	No	91.3	85.9, 96.7	No	

*Homogeneity was rejected and random-effect model used, if p -value of Q statistic was more than 0.10.

Dipyridamole, Dobutamine, and Adenosine, although there was no statistically significant difference between them. Because the SROC analysis can indicate the overall test performance but cannot distinguish individual features of these modalities, we calculated the weighted mean of LR_{\pm} and sensitivity/specificity. We hope that this will be most usable for clinicians. The slope of the tangent line at a given cut-off point of ROC curve gives the LR_{+} for the value of the test. Positive results in tests with high LR_{+} value (or specificity) have high post-test likelihoods of disease: ‘rule-in disease’, and negative results in tests with low LR_{-} value (or sensitivity) lead to low post-test likelihoods of disease: ‘rule-out disease’. Both LR_{+} and LR_{-} (or both sensitivity and specificity) were excellent for Tap-TEE. But, we should take the results for Tap-TEE with a grain of salt, because it may pertain to a relatively small experience from a few special sites. The infeasibility also hinders wide use of this modality. Exercise had satisfactory LR_{+} and LR_{-} and was considered as a standard stressor in stress echocardiography. Dipyridamole had a very high LR_{+} (or specificity) but low LR_{-} (or sensitivity). These findings suggest that Dipyridamole might be good for ruling-in but not for ruling out CAD. The incapability in ruling-out CAD (i.e., high FPR) is a major problem in clinical application of Dipyridamole stress. Adenosine was the least useful stressor in diagnosing CAD.

Our analysis results differ from previous studies. Kim and colleagues reported that test performance of Dobutamine echocardiography was superior to that of Dipyridamole [175]. Our analysis showed that the SROC curves for Dipyridamole and Dobutamine crossed each other, so neither was clearly better. Because the shape of Kim’s SROC curves resembles those of ours, the discrepancy might be accounted for by comparing the different parts of an identical curve.

Age appears to affect test characteristics. Fleischmann reported that increasing mean age of the study population decreased test performance of Exercise echocardiography and SPECT [172]. Our analysis confirmed this finding for Exercise but not for the other stressors. One potential

Table 3. Results of sensitivity analysis according to study quality.

	Number of studies	LR_{+}	95% CI	Heterogeneity	LR_{-}	95% CI	Heterogeneity	LR_{+}/LR_{-} ratio
Exercise	33	7.8	6.3, 9.3	Yes*	0.3	0.2, 0.4	No	28.6
Adenosine	8	8.8	4.3, 13.3	Yes*	0.7	0.2, 1.1	Yes*	13.6
Dobutamine	61	7.1	6.1, 8.1	Yes*	0.3	0.3, 0.4	No	21.0
Dipyridamole	36	13.9	11.6, 16.2	Yes*	0.4	0.3, 0.5	No	35.9
TAP-TTE	4	5.2	2.9, 7.6	Yes*	0.2	0, 0.7	No	24.9
TAP-TEE	4	10.8	6, 15.6	Yes*	0.2	0, 0.7	No	59.0
	Number of studies	Sensitivity	95% CI	Heterogeneity	Specificity	95% CI	Heterogeneity	
Exercise	33	82.5	79.2, 85.9	Yes*	84.1	79.4, 88.9	Yes*	
Adenosine	8	65.2	50.3, 80.1	Yes*	81.3	57.1, 100	Yes*	
Dobutamine	61	78.5	75.4, 81.5	Yes*	85.9	83.5, 88.2	Yes*	
Dipyridamole	36	71.8	67.8, 75.8	Yes*	91.6	88.3, 94.8	Yes*	
TAP-TTE	4	90.7	86.1, 95.4	No	83.7	75.3, 92	No	
TAP-TEE	4	85.3	78.2, 92.5	No	90.7	83.8, 97.5	No	

$LR_{+/-}$ and sensitivity/specificity were recalculated using studies with quality scores > 6.

*Homogeneity was rejected and random-effect model used, if *p*-value of *Q* statistic was more than 0.10.

Table 4. Summary of previous meta-analyses.

Author	Year of publication	Stressor	Imaging modality	Statistical method	Analysis of heterogeneity
O'Keefe	1995	Exercise, adenosine, dipyridamole, dobutamine	Echo/SPECT	Pooled se/sp	No
Fleischmann	1998	Exercise	Echo/SPECT	Pooled se/sp, SROC	Yes
Kwok. ^a	1999	Exercise	Echo/SPECT/ECG	Pooled LR, pooled se/sp	No
Picano ^b	2000	Dipyridamole, dobutamine	Echo	Pooled se/sp	No
Kim	2001	Adenosine, dipyridamole, dobutamine	Echo/SPECT	Pooled se/sp, SROC	No

^aStudy population is limited to women.

^bHead to head comparison of dipyridamole and dobutamine.

explanatory hypothesis is that limited exercise performance, such as with leg problems commonly seen in the elderly, results in sub-optimal stress and poorer test performance. Further investigation focusing on relationship of exercise capacity and diagnostic test performance is necessary to answer this question.

Previous meta-analyses reported that gender was not a significant predictor of test performance for Exercise and Dobutamine [172, 173, 175]. However, we observed that studies with a high proportion of female patients had a worse performance in Adenosine. Further analysis was hampered by the paucity of presented gender-specific data.

In general, the performance diagnostic tests decrease with time [177, 178]. Fleischmann similarly found that the discriminatory power of Exercise echocardiography diminished slightly with later publication year [172], but our analysis did not discern any effect of publication year on test performance.

Low quality studies that contained more biases tended to overestimate test performance [1]. These drawbacks to the validity of a diagnostic study include case-control study design, non-consecutive entry of patients, verification bias, non-blinded interpretation of test results, non-blinded interpretation of gold standard results, retrospective data collection, insufficient test details, insufficient gold standard details, and insufficient patient population details. We excluded studies with case-control design, which was the most influential factor in Lijmer's report. We examined the influence of other factors by performing regression analyses and sensitivity analysis according to the modified Lijmer's quality score. Our analyses showed no clear effect related to the quality of the primary study or verification bias. This observation agrees with a previous report [175].

There are many limitations to meta-analytic overviews of diagnostic tests. First, all studies were non-randomized and biases could distort the results of the meta-analysis in spite of our efforts to remove or control for them. Second, there is no control for the pre-test likelihood of disease. Because the performance of a diagnostic test is strongly influenced by the population that is

studied, the diversity in pre-test likelihood is a potential source of heterogeneity. We must admit that we could not control the heterogeneity completely. Third, large variation in reporting of methods and results prevented us from being able to determine key study characteristics, such as study cohort, technique used, and derivations of gold standard information (e.g., details in angiographic severity that is considered positive for CAD). As a result, it is possible that we could have underestimated or overestimated the effect of clinical covariates in their evaluation. Finally, publication bias may be present, although there are no studies which address methods to evaluate publication bias for diagnostic test. Despite these limitations, meta-analytic overview provides the current best information in making clinical decision and is a practical aid in choosing a cardiac imaging test for patients with suspected CAD.

In summary, Tap-TEE had the best overall test performance, followed by Exercise, Dipyridamole, Dobutamine, and Adenosine. Tap-TEE is a very accurate test for both ruling-in and ruling-out CAD although its invasiveness may limit its clinical acceptability. Exercise is a well-balanced satisfactory test for both ruling-in and ruling-out CAD but the performance might be lower for elderly patients. Dobutamine offers a reasonable compromise for Exercise. Dipyridamole might be good for ruling-in but not for ruling out CAD. The incapability in ruling-out CAD was a major problem in clinical application of the stress. Adenosine was the least useful stressor in diagnosing CAD.

Acknowledgement

This study was supported by Health and Labour Sciences Research Grants for Research on Health Technology Assessment from the Ministry of Health and Welfare of Japan.

Appendix

Criteria for evaluation of study quality

Each item was scored as 1 point if the corresponding criterion was fulfilled.

Blind interpretation of tests was required that blinded by clearly stated in the text. Similarly, consecutive and prospective data collection had to be mentioned explicitly. Verification bias was assessed according to the clinical context and by determining if patients did not undergo the gold standard test. Study population description required two of the following characteristics: age, gender, or distribution of symptoms. Test description required clear definitions of positivity criteria. Case-controlled design was inferred if the test was evaluated in a group of patients already known to have the disease and in a separate group of healthy volunteers rather than in a relevant clinical population.

References

1. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. *JAMA* 1999; 282(11): 1061–1066.
2. Midgette AS, Stukel TA, Littenberg B. A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. *Med Decis Making* 1993; 13(3): 253–257.
3. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. *Med Decis Making* 1993; 13(4): 313–321.
4. de Vries SO, Hunink MG, Polak JF. Summary receiver operating characteristic curves as a technique for meta-analysis of the diagnostic performance of duplex ultrasonography in peripheral arterial disease. *Acad Radiol* 1996; 3(4): 361–369.
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clin Trials* 1986; 7(3): 177–188.
6. Pettiti DB. *Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. Methods for Quantitative Synthesis in Medicine.* New York, NY: Oxford University Press, 1994.
7. Stata/SE 8.0 for Windows program]. Stata Corporation, 2003.
8. Berberich SN, Zager JR. Hybrid exercise echocardiograph. *Angiology* 1981; 32(1): 1–15.
9. Maurer G, Nanda NC. Two dimensional echocardiographic evaluation of exercise-induced left and right ventricular asynergy: correlation with thallium scanning. *Am J Cardiol* 1981; 48(4): 720–727.
10. Mitamura H, Ogawa S, Hori S, Yamazaki H, Handa S, Nakamura Y. Two dimensional echocardiographic analysis of wall motion abnormalities during handgrip exercise in patients with coronary artery disease. *Am J Cardiol* 1981; 48(4): 711–719.

11. Morganroth J, Chen CC, David D, et al. Exercise cross-sectional echocardiographic diagnosis of coronary artery disease. *Am J Cardiol* 1981; 47(1): 20–26.
12. Limacher MC, Quinones MA, Poliner LR, Nelson JG, Winters WL, Jr., Waggoner AD. Detection of coronary artery disease with exercise two-dimensional echocardiography. Description of a clinically applicable method and comparison with radionuclide ventriculography. *Circulation* 1983; 67(6): 1211–1218.
13. Robertson WS, Feigenbaum H, Armstrong WF, Dillon JC, O'Donnell J, McHenry PW. Exercise echocardiography: a clinically practical addition in the evaluation of coronary artery disease. *J Am Coll Cardiol* 1983; 2(6): 1085–1091.
14. Visser CA, van der Wieken RL, Kan G, et al. Comparison of two-dimensional echocardiography with radionuclide angiography during dynamic exercise for the detection of coronary artery disease. *Am Heart J* 1983; 106(3): 528–534.
15. Armstrong WF, O'Donnell J, Dillon JC, McHenry PL, Morris SN, Feigenbaum H. Complementary value of two-dimensional exercise echocardiography to routine treadmill exercise testing. *Ann Intern Med* 1986; 105(6): 829–835.
16. Iliceto S, D'Ambrosio G, Sorino M, et al. Comparison of postexercise and transesophageal atrial pacing two-dimensional echocardiography for detection of coronary artery disease. *Am J Cardiol* 1986; 57(8): 547–553.
17. Ryan T, Vasey CG, Presti CF, O'Donnell JA, Feigenbaum H, Armstrong WF. Exercise echocardiography: detection of coronary artery disease in patients with normal left ventricular wall motion at rest. *J Am Coll Cardiol* 1988; 11(5): 993–999.
18. Sawada SG, Ryan T, Fineberg NS, et al. Exercise echocardiographic detection of coronary artery disease in women. *J Am Coll Cardiol* 1989; 14(6): 1440–1447.
19. Alam M, Høglund C, Thorstrand C, Carlens P. Effects of exercise on the displacement of the atrioventricular plane in patients with coronary artery disease. A new echocardiographic method of detecting reversible myocardial ischemia. *Eur Heart J* 1991; 12(7): 760–765.
20. Crouse LJ, Harbrecht JJ, Vacek JL, Rosamond TL, Kramer PH. Exercise echocardiography as a screening test for coronary artery disease and correlation with coronary arteriography. *Am J Cardiol* 1991; 67(15): 1213–1218.
21. Galanti G, Sciagra R, Comeglio M, et al. Diagnostic accuracy of peak exercise echocardiography in coronary artery disease: comparison with thallium-201 myocardial scintigraphy. *Am Heart J* 1991; 122(6): 1609–1616.
22. Pozzoli MM, Fioretti PM, Salustri A, Reijns AE, Roelandt JR. Exercise echocardiography and technetium-99m MIBI single-photon emission computed tomography in the detection of coronary artery disease. *Am J Cardiol* 1991; 67(5): 350–355.
23. Fioretti PM, Pozzoli MM, Ilmer B, et al. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. *Eur Heart J* 1992; 13(2): 213–219.
24. Marwick TH, Nemeč JJ, Pashkow FJ, Stewart WJ, Salcedo EE. Accuracy and limitations of exercise echocardiography in a routine clinical setting. *J Am Coll Cardiol* 1992; 19(1): 74–81.
25. Marwick TH, Nemeč JJ, Stewart WJ, Salcedo EE. Diagnosis of coronary artery disease using exercise echocardiography and positron emission tomography: comparison and analysis of discrepant results. *J Am Soc Echocardiogr* 1992; 5(3): 231–238.
26. Quinones MA, Verani MS, Haichin RM, Mahmarian JJ, Suarez J, Zoghbi WA. Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease. Analysis of 292 patients. *Circulation* 1992; 85(3): 1026–1031.
27. Salustri A, Pozzoli MM, Hermans W, et al. Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. *Am Heart J* 1992; 124(1): 75–83.
28. Salustri A, Pozzoli MM, Ilmer B, et al. Exercise echocardiography and single photon emission computed tomography in patients with left anterior descending coronary artery stenosis. *Int J Card Imaging* 1992; 8(1): 27–34.
29. Cohen JL, Ottenweller JE, George AK, Duvvuri S. Comparison of dobutamine and exercise echocardiography for detecting coronary artery disease. *Am J Cardiol* 1993; 72(17): 1226–1231.
30. Hecht HS, DeBord L, Shaw R, et al. Supine bicycle stress echocardiography versus tomographic thallium-201 exercise imaging for the detection of coronary artery disease. *J Am Soc Echocardiogr* 1993; 6(2): 177–185.
31. Hecht HS, DeBord L, Shaw R, et al. Digital supine bicycle stress echocardiography: a new technique for evaluating coronary artery disease. *J Am Coll Cardiol* 1993; 21(4): 950–956.
32. Hecht HS, DeBord L, Sotomayor N, Shaw R, Dunlap R, Ryan C. Supine bicycle stress echocardiography: peak exercise imaging is superior to postexercise imaging. *J Am Soc Echocardiogr* 1993; 6(3 Pt 1): 265–271.
33. Kujacic VG, Jablonskiene D, Emanuelsson HU. Adenosine echocardiography—an alternative to dynamic stress echocardiography. *Int J Card Imaging* 1993; 9(3): 169–177.
34. Beleslin BD, Ostojic M, Stepanovic J, et al. Stress echocardiography in the detection of myocardial ischemia. Head-to-head comparison of exercise, dobutamine, and dipyridamole tests. *Circulation* 1994; 90(3): 1168–1176.
35. Marangelli V, Iliceto S, Piccini G, De Martino G, Sorgente L, Rizzon P. Detection of coronary artery disease by digital stress echocardiography: comparison of exercise, transesophageal atrial pacing and dipyridamole echocardiography. *J Am Coll Cardiol* 1994; 24(1): 117–124.
36. Marwick TH, D'Hondt AM, Mairesse GH, et al. Comparative ability of dobutamine and exercise stress in inducing myocardial ischemia in active patients. *Br Heart J* 1994; 72(1): 31–38.
37. Williams MJ, Marwick TH, O'Gorman D, Foale RA. Comparison of exercise echocardiography with an exercise

- score to diagnose coronary artery disease in women. *Am J Cardiol* 1994; 74(5): 435–438.
38. Atar D, Ali S, Steensgaard-Hansen F, et al. The diagnostic value of exercise echocardiography in ischemic heart disease in relation to quantitative coronary arteriography. *Int J Card Imaging* 1995; 11(1): 1–7.
 39. Bjornstad K, Aakhus S, Hatle L. Comparison of digital dipyridamole stress echocardiography and upright bicycle stress echocardiography for identification of coronary artery stenosis. *Cardiology* 1995; 86(6): 514–520.
 40. Marwick TH, Anderson T, Williams MJ, et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. *J Am Coll Cardiol* 1995; 26(2): 335–341.
 41. Marwick TH, Torelli J, Harjai K, et al. Influence of left ventricular hypertrophy on detection of coronary artery disease using exercise echocardiography. *J Am Coll Cardiol* 1995; 26(5): 1180–1186.
 42. Roger VL, Pellikka PA, Oh JK, Miller FA, Seward JB, Tajik AJ. Stress echocardiography. Part I. Exercise echocardiography: techniques, implementation, clinical applications, and correlations. *Mayo Clin Proc* 1995; 70(1): 5–15.
 43. Tawa CB, Baker WB, Kleiman NS, Trakhtenbroit A, Desir R, Zoghbi WA. Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. *J Am Soc Echocardiogr* 1996; 9(1): 33–43.
 44. Tian J, Zhang G, Wang X, Cui J, Xiao J. Exercise echocardiography: feasibility and value for detection of coronary artery disease. *Chin Med J (Engl)* 1996; 109(5): 381–384.
 45. Toumanidis ST, Pantelia MI, Trika CO, et al. Detection of coronary artery disease in the presence of left ventricular atrophy. *Int J Cardiol* 1996; 57(3): 245–255.
 46. Roger VL, Pellikka PA, Bell MR, Chow CW, Bailey KR, Seward JB. Sex and test verification bias. Impact on the diagnostic value of exercise echocardiography. *Circulation* 1997; 95(2): 405–410.
 47. Badruddin SM, Ahmad A, Mickelson J, et al. Supine bicycle versus post-treadmill exercise echocardiography in the detection of myocardial ischemia: a randomized single-blind crossover trial. *J Am Coll Cardiol* 1999; 33(6): 1485–1490.
 48. Loimaala A, Groundstroem K, Pasanen M, Oja P, Vuori I. Comparison of bicycle, heavy isometric, dipyridamole-atropine and dobutamine stress echocardiography for diagnosis of myocardial ischemia. *Am J Cardiol* 1999; 84(12): 1396–1400.
 49. Peteiro J, Fabregas R, Montserrat L, Alvarez N, Castro-Beiras A. Comparison of treadmill exercise echocardiography before and after exercise in the evaluation of patients with known or suspected coronary artery disease. *J Am Soc Echocardiogr* 1999; 12(12): 1073–1079.
 50. Chaudhry FA, Tauke JT, Alessandrini RS, Greenfield SA, Tommaso CL, Bonow RO. Enhanced detection of ischemic myocardium by transesophageal dobutamine stress echocardiography: comparison with simultaneous transthoracic echocardiography. *Echocardiography* 2000; 17(3): 241–253.
 51. Pasiński T, Szwed H, Malczewska B, et al. Advantages of exercise echocardiography in comparison to dobutamine echocardiography in the diagnosis of coronary artery disease in hypertensive subjects. *J Hum Hypertens* 2001; 15(11): 805–809.
 52. Nguyen T, Heo J, Ogilby JD, Iskandrian AS. Single photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia: correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography. *J Am Coll Cardiol* 1990; 16(6): 1375–1383.
 53. Edlund A, Albertsson P, Caidahl K, Emanuelsson H, Wallentin I. Adenosine infusion to patients with ischaemic heart disease may provoke left ventricular dysfunction detected by echocardiography. *Clin Physiol* 1991; 11(5): 477–488.
 54. Zoghbi WA, Cheirif J, Kleiman NS, Verani MS, Trakhtenbroit A. Diagnosis of ischemic heart disease with adenosine echocardiography. *J Am Coll Cardiol* 1991; 18(5): 1271–1279.
 55. Amanullah AM, Bevegard S, Lindvall K, Aasa M. Assessment of left ventricular wall motion in angina pectoris by two-dimensional echocardiography and myocardial perfusion by technetium-99m sestamibi tomography during adenosine-induced coronary vasodilation and comparison with coronary angiography. *Am J Cardiol* 1993; 72(14): 983–989.
 56. Marwick T, Willemart B, D'Hondt AM, et al. Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. *Circulation* 1993; 87(2): 345–354.
 57. Fukai T, Koyanagi S, Tashiro H, et al. Adenosine triphosphate stress echocardiography in the detection of myocardial ischemia. *Am J Card Imaging* 1995; 9(4): 237–244.
 58. Anthopoulos LP, Bonou MS, Kardaras FG, et al. Stress echocardiography in elderly patients with coronary artery disease: applicability, safety and prognostic value of dobutamine and adenosine echocardiography in elderly patients. *J Am Coll Cardiol* 1996; 28(1): 52–59.
 59. Djordjevic-Dikic AD, Ostojic MC, Beleslin BD, et al. High dose adenosine stress echocardiography for noninvasive detection of coronary artery disease. *J Am Coll Cardiol* 1996; 28(7): 1689–1695.
 60. Miyazono Y, Kisanuki A, Toyonaga K, et al. Usefulness of adenosine triphosphate-atropine stress echocardiography for detecting coronary artery stenosis. *Am J Cardiol* 1998; 82(3): 290–294.
 61. Cohen JL, Greene TO, Ottenweller J, Binenbaum SZ, Wilchfort SD, Kim CS. Dobutamine digital echocardiography for detecting coronary artery disease. *Am J Cardiol* 1991; 67(16): 1311–1318.

62. Previtali M, Lanzarini L, Ferrario M, Tortorici M, Mussini A, Montemartini C. Dobutamine versus dipyridamole echocardiography in coronary artery disease. *Circulation*. 1991; 83(5 Suppl): III27-III31.
63. Sawada SG, Segar DS, Ryan T, et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. *Circulation* 1991; 83(5): 1605-1614.
64. Epstein M, Gin K, Sterns L, Pollick C. Dobutamine stress echocardiography: initial experience of a Canadian centre. *Can J Cardiol* 1992; 8(3): 273-279.
65. Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. *Am J Cardiol* 1992; 69(16): 1269-1273.
66. Mazeika PK, Nadazdin A, Oakley CM. Dobutamine stress echocardiography for detection and assessment of coronary artery disease. *J Am Coll Cardiol* 1992; 19(6): 1203-1211.
67. McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt JR. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. *Am J Cardiol* 1992; 70(1): 41-46.
68. Salustri A, Fioretti PM, Pozzoli MM, McNeill AJ, Roelandt JR. Dobutamine stress echocardiography: its role in the diagnosis of coronary artery disease. *Eur Heart J* 1992; 13(1): 70-77.
69. Salustri A, Fioretti PM, McNeill AJ, Pozzoli MM, Roelandt JR. Pharmacological stress echocardiography in the diagnosis of coronary artery disease and myocardial ischaemia: a comparison between dobutamine and dipyridamole. *Eur Heart J* 1992; 13(10): 1356-1362.
70. Segar DS, Brown SE, Sawada SG, Ryan T, Feigenbaum H. Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography. *J Am Coll Cardiol* 1992; 19(6): 1197-1202.
71. Forster T, McNeill AJ, Salustri A, et al. Simultaneous dobutamine stress echocardiography and technetium-99m isonitrile single-photon emission computed tomography in patients with suspected coronary artery disease. *J Am Coll Cardiol* 1993; 21(7): 1591-1596.
72. Gunalp B, Dokumaci B, Uyan C, et al. Value of dobutamine technetium-99m-sestamibi SPECT and echocardiography in the detection of coronary artery disease compared with coronary angiography. *J Nucl Med* 1993; 34(6): 889-894.
73. Marwick T, D'Hondt AM, Baudhuin T, et al. Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? *J Am Coll Cardiol* 1993; 22(1): 159-167.
74. Mazeika PK, Nadazdin A, Oakley CM. Prognostic value of dobutamine echocardiography in patients with high pretest likelihood of coronary artery disease. *Am J Cardiol* 1993; 71(1): 33-39.
75. Previtali M, Lanzarini L, Fetiveau R, et al. Comparison of dobutamine stress echocardiography, dipyridamole stress echocardiography and exercise stress testing for diagnosis of coronary artery disease. *Am J Cardiol* 1993; 72(12): 865-870.
76. Takeuchi M, Araki M, Nakashima Y, Kuroiwa A. Comparison of dobutamine stress echocardiography and stress thallium-201 single-photon emission computed tomography for detecting coronary artery disease. *J Am Soc Echocardiogr* 1993; 6(6): 593-602.
77. Warner MF, Pippin JJ, DiSciascio G, et al. Assessment of thallium scintigraphy and echocardiography during dobutamine infusion for the detection of coronary artery disease. *Cathet Cardiovasc Diagn* 1993; 29(2): 122-127.
78. Mairesse GH, Marwick TH, Vanoverschelde JL, et al. How accurate is dobutamine stress electrocardiography for detection of coronary artery disease? Comparison with two-dimensional echocardiography and technetium-99m methoxy isobutyl isonitrile (mibi) perfusion scintigraphy. *J Am Coll Cardiol* 1994; 24(4): 920-927.
79. Ostojic M, Picano E, Beleslin B, et al. Dipyridamole-dobutamine echocardiography: a novel test for the detection of milder forms of coronary artery disease. *J Am Coll Cardiol* 1994; 23(5): 1115-1122.
80. Panza JA, Laurienzo JM, Curiel RV, Quyyumi AA, Cannon RO, 3rd. Transesophageal dobutamine stress echocardiography for evaluation of patients with coronary artery disease. *J Am Coll Cardiol* 1994; 24(5): 1260-1267.
81. Prince CR, Stoddard MF, Morris GT, et al. Dobutamine two-dimensional transesophageal echocardiographic stress testing for detection of coronary artery disease. *Am Heart J* 1994; 128(1): 36-41.
82. Sahin M, Karakelleoglu S, Alp N, Atesal S, Senocak H. Diagnostic value of dobutamine stress echocardiography in coronary artery disease. *Thorac Cardiovasc Surg* 1994; 42(5): 285-289.
83. Santiago P, Vacek JL, Rosamond TL. Dobutamine stress echocardiography: clinical utility and predictive value at various infusion rates. *Am Heart J* 1994; 128(4): 804-808.
84. Senior R, Sridhara BS, Anagnostou E, Handler C, Rafferty EB, Lahiri A. Synergistic value of simultaneous stress dobutamine sestamibi single-photon-emission computerized tomography and echocardiography in the detection of coronary artery disease. *Am Heart J* 1994; 128(4): 713-718.
85. Castini D, Gentile F, Ornaghi M, et al. Dobutamine echocardiography: usefulness of digital image processing. *Eur Heart J* 1995; 16(10): 1420-1424.
86. Chan RK, Tonkin AM, Byrgiotis S, Calafiore P. Assessment of coronary artery disease by dobutamine stress echocardiography (DSE). *Aust N Z J Med* 1995; 25(6): 707-715.
87. Daoud EG, Pitt A, Armstrong WF. Electrocardiographic response during dobutamine stress echocardiography. *Am Heart J* 1995; 129(4): 672-677.
88. Frohwein S, Klein JL, Lane A, Taylor WR. Transesophageal dobutamine stress echocardiography in the evaluation of coronary artery disease. *J Am Coll Cardiol* 1995; 25(4): 823-829.
89. Geleijnse ML, Marwick TH, Boersma E, Deckers JW, Melin JA, Fioretti PM. Optimal pharmacological stress testing for the diagnosis of coronary artery disease: a

- probabilistic approach. *Eur Heart J* 1995; 16(Suppl M): 3–10.
90. Latham AP, Orsinelli DA, Pearson AC. Recognition of the segmental tendency of false-positive dobutamine stress echocardiograms and its effects on test sensitivity and specificity. *Am Heart J* 1995; 129(5): 1047–1050.
 91. Mairesse GH, Marwick TH, Arnese M, et al. Improved identification of coronary artery disease in patients with left bundle branch block by use of dobutamine stress echocardiography and comparison with myocardial perfusion tomography. *Am J Cardiol* 1995; 76(5): 321–325.
 92. Reis G, Marcovitz PA, Leichtman AB, et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. *Am J Cardiol* 1995; 75(10): 707–710.
 93. Sochowski RA, Yvorchuk KJ, Yang Y, Rattes MF, Chan KL. Dobutamine and dipyridamole stress echocardiography in patients with a low incidence of severe coronary artery disease. *J Am Soc Echocardiogr* 1995; 8(4): 482–487.
 94. De Bello V, Bellina CR, Molea N, et al. Simultaneous dobutamine stress echocardiography and dobutamine scintigraphy (99mTc-MIBI-SPET) for assessment of coronary artery disease. *Int J Card Imaging* 1996; 12(3): 185–190.
 95. Elhendy A, Geleijnse L, Salustri A, et al. T wave normalization during dobutamine stress testing in patients with non-Q wave myocardial infarction. A marker of myocardial ischaemia? *Eur Heart J* 1996; 17(4): 526–531.
 96. Elhendy A, van Domburg RT, Roelandt JR, et al. Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction. *Heart* 1996; 76(2): 123–128.
 97. Hoffmann R, Lethen H, Marwick T, et al. Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. *J Am Coll Cardiol* 1996; 27(2): 330–336.
 98. Iwase M, Fukui M, Tamagaki H, et al. Advantages and disadvantages of dobutamine stress echocardiography compared with treadmill exercise electrocardiography in detecting ischemia. *Jpn Circ J* 1996; 60(12): 954–960.
 99. Pingitore A, Picano E, Colosso MQ, et al. The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. *J Am Coll Cardiol* 1996; 27(5): 1164–1170.
 100. San Roman JA, Vilacosta I, Castillo JA, et al. Dipyridamole and dobutamine-atropine stress echocardiography in the diagnosis of coronary artery disease. Comparison with exercise stress test, analysis of agreement, and impact of antianginal treatment. *Chest* 1996; 110(5): 1248–1254.
 101. Senior R, Basu S, Handler C, Raftery EB, Lahiri A. Diagnostic accuracy of dobutamine stress echocardiography for detection of coronary heart disease in hypertensive patients. *Eur Heart J* 1996; 17(2): 289–295.
 102. Takeuchi M, Sonoda S, Miura Y, Kuroiwa A. Comparative diagnostic value of dobutamine stress echocardiography and stress thallium-201 single-photon-emission computed tomography for detecting coronary artery disease in women. *Coron Artery Dis* 1996; 7(11): 831–835.
 103. Yeo TC, Ling LH, Ng WL, et al. Dobutamine stress echocardiography: angiographic correlates. *Ann Acad Med Singapore* 1996; 25(2): 196–199.
 104. Hennessy TG, Codd MB, Kane G, McCarthy C, McCann HA, Sugrue DD. Dobutamine stress echocardiography in the detection of coronary artery disease: importance of the pretest likelihood of disease. *Am Heart J* 1997; 134(4): 685–692.
 105. Hennessy TG, Codd MB, Kane G. Evaluation of patients with diabetes mellitus for coronary artery disease using dobutamine stress echocardiography. *Coron Artery Dis* 1997; 8(3–4): 171–174.
 106. Ho YL, Wu CC, Huang PJ, et al. Dobutamine stress echocardiography compared with exercise thallium-201 single-photon emission computed tomography in detecting coronary artery disease—effect of exercise level on accuracy. *Cardiology* 1997; 88(4): 379–385.
 107. Ho YL, Wu CC, Lin LC, et al. Assessment of the functional significance of coronary artery stenosis by dobutamine-atropine stress echocardiography. *Cardiology* 1997; 88(4): 386–392.
 108. Oguzhan A, Kisacik HL, Ozdemir K, et al. Comparison of exercise stress testing with dobutamine stress echocardiography and exercise technetium-99m isonitrile single photon emission computerized tomography for diagnosis of coronary artery disease. *Jpn Heart J* 1997; 38(3): 333–344.
 109. Vitarelli A, Luzzi MF, Penco M, Fedele F, Dagianti A. On-line quantitative assessment of left ventricular filling during dobutamine stress echocardiography: a useful addition to conventional wall motion scoring. *Int J Cardiol* 1997; 59(1): 57–69.
 110. Elhendy A, van Domburg RT, Bax JJ, et al. Optimal criteria for the diagnosis of coronary artery disease by dobutamine stress echocardiography. *Am J Cardiol* 1998; 82(11): 1339–1344.
 111. Elhendy A, Geleijnse ML, van Domburg RT, et al. Comparison of dobutamine stress echocardiography and technetium-99m sestamibi single-photon emission tomography for the diagnosis of coronary artery disease in hypertensive patients with and without left ventricular hypertrophy. *Eur J Nucl Med* 1998; 25(1): 69–78.
 112. Elhendy A, van Domburg RT, Poldermans D, et al. Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test. *Diabetes Care* 1998; 21(11): 1797–1802.
 113. Elhendy A, van Domburg RT, Bax JJ, et al. Noninvasive diagnosis of coronary artery stenosis in women with limited exercise capacity: comparison of dobutamine stress echocardiography and 99mTc sestamibi single-photon emission CT. *Chest* 1998; 114(4): 1097–1104.
 114. Hennessy TG, Siobhan Hennessy M, Codd MB, et al. Detection of coronary artery disease using dobutamine stress echocardiography in patients with an abnormal resting electrocardiograph. *Int J Cardiol* 1998; 64(3): 293–298.

115. Ho YL, Wu CC, Huang PJ, et al. Assessment of coronary artery disease in women by dobutamine stress echocardiography: comparison with stress thallium-201 single-photon emission computed tomography and exercise electrocardiography. *Am Heart J* 1998; 135(4): 655–662.
116. Ho YL, Wu CC, Lin LC, et al. Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: effect of the left ventricular hypertrophy. *Cardiology* 1998; 89(1): 52–58.
117. Khattar RS, Senior R, Lahiri A. Assessment of myocardial perfusion and contractile function by inotropic stress Tc-99m sestamibi SPECT imaging and echocardiography for optimal detection of multivessel coronary artery disease. *Heart* 1998; 79(3): 274–280.
118. San Roman JA, Vilacosta I, Castillo JA, et al. Selection of the optimal stress test for the diagnosis of coronary artery disease. *Heart* 1998; 80(4): 370–376.
119. Santoro GM, Sciagra R, Buonamici P, et al. Head-to-head comparison of exercise stress testing, pharmacologic stress echocardiography, and perfusion tomography as first-line examination for chest pain in patients without history of coronary artery disease. *J Nucl Cardiol* 1998; 5(1): 19–27.
120. Shaheen J, Luria D, Klutstein MW, Rosenmann D, Tzivoni D. Diagnostic value of 12-lead electrocardiogram during dobutamine echocardiographic studies. *Am Heart J* 1998; 136(6): 1061–1064.
121. Elhendy A, Bax JJ, van Domburg RT, et al. Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. *Eur J Nucl Med* 1999; 26(5): 467–473.
122. Fragasso G, Lu C, Dabrowski P, Pagnotta P, Sheiban I, Chierchia SL. Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. *J Am Coll Cardiol* 1999; 34(2): 441–447.
123. Herzog CA, Marwick TH, Pheley AM, White CW, Rao VK, Dick CD. Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. *Am J Kidney Dis* 1999; 33(6): 1080–1090.
124. Hoffmann R, Lethen H, Kuhl H, Lepper W, Hanrath P. Extent and severity of test positivity during dobutamine stress echocardiography. Influence on the predictive value for coronary artery disease. *Eur Heart J* 1999; 20(20): 1485–1492.
125. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. *Circulation* 1999; 99(6): 763–770.
126. Ozdemir K, Kisacik HL, Oguzhan A, et al. Comparison of exercise stress testing with dobutamine stress echocardiography and radionuclide ventriculography for diagnosis of coronary artery disease. *Jpn Heart J* 1999; 40(6): 715–727.
127. Therre T, Ribal JP, Motreff P, et al. Assessment of cardiac risk before aortic reconstruction: noninvasive work-up using clinical examination, exercise testing, and dobutamine stress echocardiography versus routine coronary arteriography. *Ann Vasc Surg* 1999; 13(5): 501–508.
128. Ariff B, Thom SA, Foale RA, Mayet J. Stress echocardiography for the diagnosis of ischaemia in hypertensives. *J Hum Hypertens* 2000; 14(6): 399–401.
129. Joseph T, Vieillard-Baron A, Chikli F, et al. Left ventricular volume analysis for the detection of coronary artery disease during dobutamine stress echocardiography in patients undergoing vascular surgery. *Eur J Echocardiogr* 2000; 1(4): 263–270.
130. Smart SC, Knickelbine T, Malik F, Sagar KB. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. *Circulation* 2000; 101(3): 258–263.
131. Ahmad M, Xie T, McCulloch M, Abreo G, Runge M. Real-time three-dimensional dobutamine stress echocardiography in assessment stress echocardiography in assessment of ischemia: comparison with two-dimensional dobutamine stress echocardiography. *J Am Coll Cardiol* 2001; 37(5): 1303–1309.
132. Dolan MS, Riad K, El-Shafei A, et al. Effect of intravenous contrast for left ventricular opacification and border definition on sensitivity and specificity of dobutamine stress echocardiography compared with coronary angiography in technically difficult patients. *Am Heart J* 2001; 142(5): 908–915.
133. Peteiro J, Monserrat L, Fabregas R, Manuel Vazquez J, Calvino R, Castro-Beiras A. Comparison of two-dimensional echocardiography and pulsed Doppler tissue imaging during dobutamine-atropine stress testing to detect coronary artery disease. *Echocardiography* 2001; 18(4): 275–284.
134. Picano E, Distanto A, Masini M, Morales MA, Lattanzi F, L'Abbate A. Dipyridamole-echocardiography test in effort angina pectoris. *Am J Cardiol* 1985; 56(7): 452–456.
135. Picano E, Lattanzi F, Masini M, Distanto A, L'Abbate A. High dose dipyridamole echocardiography test in effort angina pectoris. *J Am Coll Cardiol* 1986; 8(4): 848–854.
136. Picano E, Masini M, Lattanzi F, Distanto A, L'Abbate A. Role of dipyridamole-echocardiography test in electrocardiographically silent effort myocardial ischemia. *Am J Cardiol* 1986; 58(3): 235–237.
137. Picano E, Morales MA, Distanto A, et al. Dipyridamole-echocardiography test in angina at rest: noninvasive assessment of coronary stenosis underlying spasm. *Am Heart J* 1986; 111(4): 688–691.
138. Picano E, Lattanzi F, Masini M, Distanto A, L'Abbate A. Comparison of the high-dose dipyridamole-echocardiography test and exercise two-dimensional echocardiography for diagnosis of coronary artery disease. *Am J Cardiol* 1987; 59(6): 539–542.
139. Masini M, Picano E, Lattanzi F, Distanto A, L'Abbate A. High dose dipyridamole-echocardiography test in women:

- correlation with exercise-electrocardiography test and coronary arteriography. *J Am Coll Cardiol* 1988; 12(3): 682–685.
140. Picano E, Masini M, Lattanzi F, et al. Short term reproducibility of exercise testing in patients with ST segment elevation and different responses to the dipyridamole test. *Br Heart J* 1988; 60(4): 281–286.
 141. Picano E, Lattanzi F, Masini M, Distanti A, L'Abbate A. Usefulness of the dipyridamole-exercise echocardiography test for diagnosis of coronary artery disease. *Am J Cardiol* 1988; 62(1): 67–70.
 142. Picano E, Severi S, Michelassi C, et al. Prognostic importance of dipyridamole-echocardiography test in coronary artery disease. *Circulation* 1989; 80(3): 450–457.
 143. Ferrara N, Leosco D, Abete P, et al. Dipyridamole echocardiography as a useful and safe test in the assessment of coronary artery disease in the elderly. *J Am Geriatr Soc* 1991; 39(10): 993–999.
 144. Mandysova E, Niederle P, Malkova A, et al. Usefulness of dipyridamole-handgrip echocardiography test for detecting coronary artery disease. *Am J Cardiol* 1991; 67(9): 883–885.
 145. Perin EC, Moore W, Blume M, Hernandez G, Dhekne R, DeCastro CM. Comparison of dipyridamole-echocardiography with dipyridamole-thallium scintigraphy for the diagnosis of myocardial ischemia. *Clin Nucl Med* 1991; 16(6): 417–420.
 146. Picano E, Lattanzi F, Orlandini A, Marini C, L'Abbate A. Stress echocardiography and the human factor: the importance of being expert. *J Am Coll Cardiol* 1991; 17(3): 666–669.
 147. Agati L, Renzi M, Sciomè S, et al. Transesophageal dipyridamole echocardiography for diagnosis of coronary artery disease. *J Am Coll Cardiol* 1992; 19(4): 765–770.
 148. Lattanzi F, Picano E, Frugoli A, et al. Oral vs intravenous dipyridamole echocardiography for detecting coronary artery disease. *Chest* 1992; 102(4): 1189–1192.
 149. Mazeika P, Nihoyannopoulos P, Joshi J, Oakley CM. Uses and limitations of high dose dipyridamole stress echocardiography for evaluation of coronary artery disease. *Br Heart J* 1992; 67(2): 144–149.
 150. Bjornstad K, Aakhus S, Lundbom J, et al. Digital dipyridamole stress echocardiography in silent ischemia after coronary artery bypass grafting and/or after healing of acute myocardial infarction. *Am J Cardiol* 1993; 72(9): 640–646.
 151. Picano E, Pingitore A, Conti U, et al. Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dipyridamole echocardiography. *Eur Heart J* 1993; 14(9): 1216–1222.
 152. Severi S, Picano E, Michelassi C, et al. Diagnostic and prognostic value of dipyridamole echocardiography in patients with suspected coronary artery disease. Comparison with exercise electrocardiography. *Circulation* 1994; 89(3): 1160–1173.
 153. Bjornstad K, Aakhus S, Hatle L. Digital high frame rate stress echocardiography for detection of coronary artery stenosis by high dose dipyridamole stress testing. *Int J Card Imaging* 1995; 11(3): 163–170.
 154. Lanzarini L, Fetiveau R, Poli A, Diotallevi P, Barberis P, Previtali M. Results of dipyridamole plus atropine echo stress test for the diagnosis of coronary artery disease. *Int J Card Imaging* 1995; 11(4): 233–240.
 155. Wagdi P, Kaufmann U, Fluri M, Meier B. High dose dipyridamole as a pharmacological stress test during cardiac catheterisation in patients with coronary artery disease. *Heart* 1996; 75(3): 247–251.
 156. Bjornstad K, Aakhus S, Torp HG. How does computer-assisted digital wall motion analysis influence observer agreement and diagnostic accuracy during stress echocardiography? *Int J Card Imaging* 1997; 13(2): 105–114.
 157. Gaddi O, Tortorella G, Picano E, et al. Diagnostic and prognostic value of vasodilator stress echocardiography in asymptomatic Type 2 diabetic patients with positive exercise thallium scintigraphy: a pilot study. *Diabet Med* 1999; 16(9): 762–766.
 158. Parodi G, Picano E, Marcassa C, et al. High dose dipyridamole myocardial imaging: simultaneous sestamibi scintigraphy and two-dimensional echocardiography in the detection and evaluation of coronary artery disease. Italian Group of Nuclear Cardiology. *Coron Artery Dis* 1999; 10(3): 177–184.
 159. Astarita C, Palinkas A, Nicolai E, Maresca FS, Varga A, Picano E. Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. *J Hypertens* 2001; 19(3): 495–502.
 160. Zabalgoitia M, Gandhi DK, Abi-Mansour P, Yarnold PR, Moushmouth B, Rosenblum J. Transesophageal stress echocardiography: detection of coronary artery disease in patients with normal resting left ventricular contractility. *Am Heart J* 1991; 122(5): 1456–1463.
 161. de Cock CC, Kamp O, Meijer A. Identifying patients for rate responsive atrial pacing: a new method for patient selection and pacemaker programming. *Pacing Clin Electrophysiol* 1992; 15(11 Pt 2): 1792–1797.
 162. Kamp O, De Cock CC, Kupper AJ, Roos JP, Visser CA. Simultaneous transesophageal two-dimensional echocardiography and atrial pacing for detecting coronary artery disease. *Am J Cardiol* 1992; 69(17): 1412–1416.
 163. Norris LP, Stewart RE, Jain A, Hibner CS, Chaudhuri TK, Zabalgoitia M. Biplane transesophageal pacing echocardiography compared with dipyridamole thallium-201 single-photon emission computed tomography in detecting coronary artery disease. *Am Heart J* 1993; 126(3 Pt 1): 676–685.
 164. Hoffmann R, Kleinhans E, Lambert H, et al. Transesophageal pacing echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. *Eur Heart J* 1994; 15(6): 823–831.
 165. Michael TA, Rao G, Balasingam S. Accuracy and usefulness of atrial pacing in conjunction with transesophageal echocardiography in the detection of cardiac ischemia (a comparative study with scintigraphic tomography and coronary arteriography). *Am J Cardiol* 1995; 75(8): 563–567.
 166. Iliceto S, Sorino M, D'Ambrosio G, et al. Detection of coronary artery disease by two-dimensional echocardiography and transesophageal atrial pacing. *J Am Coll Cardiol* 1985; 5(5): 1188–1197.

167. Matthews RV, Haskell RJ, Ginzton LE, Laks MM. Usefulness of esophageal pill electrode atrial pacing with quantitative two-dimensional echocardiography for diagnosing coronary artery disease. *Am J Cardiol* 1989; 64(12): 730–735.
168. Laucevicius A, Berukstis E, Kosinskas E, Jablonskiene D, Ivaskeviciene L. Quantitative assessment of transient left ventricular asynergy in coronary artery disease. *Clin Cardiol* 1991; 14(2): 105–110.
169. Michael TA, Antonescu A, Bhambi B, Balasingam S. Accuracy and usefulness of atrial pacing in conjunction with transthoracic echocardiography in the detection of cardiac ischemia. *Am J Cardiol* 1996; 77(2): 187–190.
170. Atar S, Nagai T, Cercek B, Naqvi TZ, Luo H, Siegel RJ. Pacing stress echocardiography: an alternative to pharmacologic stress testing. *J Am Coll Cardiol* 2000; 36(6): 1935–1941.
171. O'Keefe J, Jr, Barnhart C, Bateman T. Comparison of stress echocardiography and stress myocardial perfusion scintigraphy for diagnosing coronary artery disease and assessing its severity. *Am J Cardiol* 1995; 75(11): 25D–34D.
172. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. *JAMA* 1998; 280(10): 913–920.
173. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. *Am J Cardiol* 1999; 83(5): 660–666.
174. Picano E, Bedetti G, Varga A, Cseh E. The comparable diagnostic accuracies of dobutamine-stress and dipyridamole-stress echocardiographies: a meta-analysis. *Coron Artery Dis* 2000; 11(2): 151–159.
175. Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: a meta-analysis. *Am Heart J* 2001; 142(6): 934–944.
176. Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. *Ann Intern Med* 1994; 120(8): 667–676.
177. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. *N Engl J Med* 1978; 299(17): 926–930.
178. Rozanski A, Diamond GA, Berman D, Forrester JS, Morris D, Swan HJ. The declining specificity of exercise radionuclide ventriculography. *N Engl J Med* 1983; 309(9): 518–522.

Address for correspondence: Yoshinori Noguchi, Department of General Internal Medicine, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake-city, Aichi prefecture 470-1192, Japan
Tel.: +81-0562-93-2000; Fax: +81-0562-93-3797
E-mail: yoshi-noguchi@umin.ac.jp